Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beam Therapeutics (BEAM) Other financing activities (2019 - 2023)

Beam Therapeutics (BEAM) has disclosed Other financing activities for 5 consecutive years, with $384000.0 as the latest value for Q3 2023.

  • On a quarterly basis, Other financing activities rose 1436.0% to $384000.0 in Q3 2023 year-over-year; TTM through Dec 2023 was $631000.0, a 235.64% increase, with the full-year FY2023 number at $631000.0, up 235.64% from a year prior.
  • Other financing activities was $384000.0 for Q3 2023 at Beam Therapeutics, up from $185000.0 in the prior quarter.
  • In the past five years, Other financing activities ranged from a high of $8.0 million in Q1 2021 to a low of $6000.0 in Q1 2022.
  • A 5-year average of $832176.5 and a median of $209000.0 in 2021 define the central range for Other financing activities.
  • Peak YoY movement for Other financing activities: crashed 99.92% in 2022, then skyrocketed 1436.0% in 2023.
  • Beam Therapeutics' Other financing activities stood at $1.4 million in 2019, then tumbled by 76.13% to $342000.0 in 2020, then tumbled by 62.57% to $128000.0 in 2021, then crashed by 57.81% to $54000.0 in 2022, then soared by 611.11% to $384000.0 in 2023.
  • Per Business Quant, the three most recent readings for BEAM's Other financing activities are $384000.0 (Q3 2023), $185000.0 (Q2 2023), and $62000.0 (Q1 2023).